ArticleInternational journal of clinical pharmacy2026
Drug-induced fever: a pharmacovigilance analysis based on the FDA adverse event reporting system.
Article in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionDrug-induced fever is a common but often under-recognized adverse reaction that can complicate clinical management.
aimThis study aimed to systematically evaluate the risk of drug-induced fever using real-world pharmacovigilance data and to characterize its temporal onset patterns and clinical features.
methodA pharmacovigilance study was conducted utilizing data from the FAERS, covering reports from the first quarter of 2004 to the fourth quarter of 2024. The detection of adverse drug event signals was conducted using disproportionality analysis. The robustness of identified fever signals was assessed through sensitivity analysis. Furthermore, a time-to-onset analysis was undertaken to elucidate factors associated with the development of drug-induced fever.
resultsDisproportionality analysis revealed that antineoplastic and immunomodulating agents were the most frequently associated, followed by antiinfectives for systemic use, alimentary tract and metabolism, musculo-skeletal system, nervous system, blood and blood forming organs, dermatologicals, genito urinary system and sexhormones. The top-five drugs with drug-induced fever signals by case number were rituximab (3650 cases), immunoglobulin human normal (2478 cases), zoledronic acid (2304 cases), lamotrigine (1843 cases), dabrafenib (1803 cases). Sensitivity analysis confirmed that the majority of the positive signals remained robust. Analysis of the time-to-onset revealed that drug-induced fever occurred predominantly during the early phase of treatment. Furthermore, female patients experienced an earlier onset compared to males.
conclusionThis large-scale pharmacovigilance analysis identified drugs and patient characteristics associated with drug-induced fever and revealed early-onset patterns, providing evidence to support its early recognition and monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.